SUMMARY
Concentric lung vascular wall thickening due to enhanced proliferation of pulmonary arterial smooth muscle cells is an important pathological cause for the elevated pulmonary vascular resistance reported in patients with pulmonary arterial hypertension. We identified a differential role of mammalian target of rapamycin (mTOR) complex 1 and complex 2, two functionally distinct mTOR complexes, in the development of pulmonary hypertension (PH). Inhibition of mTOR complex 1 attenuated the development of PH; however, inhibition of mTOR complex 2 caused spontaneous PH, potentially due to up-regulation of platelet-derived growth factor receptors in pulmonary arterial smooth muscle cells, and compromised the therapeutic effect of the mTOR inhibitors on PH. In addition, we describe a promising therapeutic strategy using combination treatment with the mTOR inhibitors and the platelet-derived growth factor receptor inhibitors on PH and right ventricular hypertrophy.
The data from this study provide an important mechanism-based perspective for developing novel therapies for patients with pulmonary arterial hypertension and right heart failure. and arteriole and precapillary muscularization (7, 8) .
Multiple mechanisms and numerous intracellular signaling cascades are involved in stimulating PASMC proliferation and migration to develop pulmonary vascular remodeling (2, (9) (10) (11) (12) (13) (14) (15) .
The phosphoinositide 3-kinase (PI3K)/ AKT/mammalian target of rapamycin (mTOR) pathway, one of the critical signaling cascades involved in cell proliferation (16) , can be activated by various growth factors and mitogenic cytokines (17) (18) (19) . We and other investigators have shown that the PI3K/Akt1/ mTOR signaling pathway plays an important role in the regulation of PASMC proliferation and the development of PH (16, 20) . Activation of the PI3K/AKT/mTOR pathway in PASMCs is through various stimuli such as platelet-derived growth factor (PDGF), endothelin-1 (21, 22) , stress, and hypoxia (23) . A relatively new topic of research in the field of pulmonary vascular disease is to understand the individual or differential roles of mTORC1 and mTORC2 in PASMC proliferation and the development of PAH/PH. The mTORC1 and mTORC2 also differ in their sensitivity to rapamycin; that is, short-term treatment with rapamycin inhibits mTORC1, but long-term treatment with rapamycin can inhibit both mTORC1 and mTORC2 (29) .
Significant research is being conducted in understanding the role of mTOR, as a common component in both mTORC1 and mTORC2, in the development of hypoxia-induced PH by promoting PASMC proliferation (30, 31) . The aim of the present study was to examine whether mTORC1 and mTORC2 potentially play a differential role in the development of PH. We generated the following: 1) smooth muscle (SM)- 
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and Raptor SMÀ/À (Tam-Cre þ /Raptor F/F ) mice exposed to normoxia (room air, 21% oxygen) and hypoxia (10% oxygen for 3 weeks). Dunn test, ***p < 0.001, **p < 0.01 versus Normoxia-WT; #p < 0.05 versus Hypoxia WT. The numbers of experiments (n) for each group are indicated in each bar. Abbreviations as in Figure 1 .
mTORC1 and mTORC2 Contribute to the Development of HPH showing cell nuclei (DAPI; blue), smooth muscle cells (SMA; red), and Rictor (dark green) in the cross-section of small PA in lung tissues from WT (Rictor-Oil) and Tang et al. during the development of HPH. 
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FIGURE 5 Rictor Deletion in Endothelial Cells Fails to Cause Spontaneous Pulmonary Hypertension
Endothelial-specific conditional and inducible KO of Rictor fails to attenuates hypoxia-induced pulmonary hypertension in Rictor ECÀ/À mice. Abbreviations as in Figure 1 .
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Tang et al. (Figures 6Aa, b and 6Ba, b) .
D E C E M B E R
The KO of Rictor would lead to inhibition of mTORC2.
Indeed, pAKT (at S473 but not at T308), a major downstream signaling protein of mTORC2, was significantly decreased in the PA isolated from and Rictor SMÀ/À mice. The numbers of experiments (n) for each group are also indicated in each bar. Abbreviations as in Figure 1 .
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Tang et al. (Figures 7Ec and 7Ed) . The low dose of imatinib (20 mg/kg) had no effect on RVSP (Figures 7Ea and 7Eb) but slightly (with statistical significance) inhibited hypoxia/Sugen -mediated increases in the Fulton index ( Figure 7Ec ) and the ratio of right ventricular weight to body weight (Figure 7Ed) . However, combination of the low doses of rapamycin and imatinib resulted in w60% inhibition of the hypoxia/Sugenmediated increase in RVSP (Figures 7Ea and 7Eb ).
These data suggest that blockade of PDGFRs using ( Figure 7D ) and increased the nuclear FOXO3a (Figures 8Bb and 8Bc) , whereas rapamycin did not significantly decrease pAKT at S473 ( Figure 7D ) and actually decreased the nuclear FOXO3a (Figure 8Bc ).
Taken together, these data indicate that inhibition of mTORC2 increases the activity of FOXO3a in PASMCs, which may be the mechanism in which PDGFR is negatively regulated by mTORC2. TRANSLATIONAL OUTLOOK: The data from these in vitro and in vivo animal studies, although with limitations, strongly suggest a combination therapeutic strategy using inhibitors of mTOR and PDGFRs for PAH and PH associated with hypoxia and lung diseases.
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